UNSPSC 51453203: Furodazole

This classification denotes an antihelminthic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9745E7HEBG. European Medicines Agency schedules Furodazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07845MIG. Furodazole generally arises in the molecular formula C15H11N3O2.

UNSPSC 51453203 Furodazole, a Commodity code, shows a significant mismatch between its nominal scope and recent state and local procurement activity. The code's title references a specific pharmaceutical compound, yet the opportunities tagged to it involve naloxone (an opioid antagonist), direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products—a broad range of health commodities and pharmacy benefit management services bearing no direct relation to furodazole. The recent solicitations indicate that state and local agencies are actually procuring emergency medical supplies, pharmaceutical distribution services, and pharmacy benefit program infrastructure rather than the specific active pharmaceutical ingredient the code nominally describes.

Issuing bodies include health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), city fire departments (Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating jurisdictions). Recent opportunities span Florida, Texas, and the Upper Midwest. Representative procurements include Seminole County's IFB60459723LAS (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually; the City of Tampa's ITB 26-P-00145 (due March 13, 2026) for medical and first aid supplies to the Tampa Fire Department Rescue Division, estimated at $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; and MMCAP's RFP S1070000015802 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. The code shows little relevant recent activity for the specific product it names, suggesting either systematic tagging misalignment or abandonment of procurements involving furodazole itself at the state and local level.